Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2024 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Leadership Updates

LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...
June 17, 2024 06:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were...
June 04, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...
June 03, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 28, 2024 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
May 14, 2024 10:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
May 08, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
March 14, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
March 05, 2024 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
February 28, 2024 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...